ACRS – aclaris therapeutics, inc. (US:NASDAQ)
Stock Stats
News
1/30
08:14 am
acrs
Low
Aclaris Therapeutics (NASDAQ:ACRS) is now covered by analysts at Craig Hallum. They set a "buy" rating on the stock.
1/28
08:41 am
acrs
Medium
Aclaris Therapeutics (NASDAQ:ACRS) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.
1/27
07:07 am
acrs
Low
Aclaris Therapeutics' Novel ITK/JAK3 Inhibitor ATI-2138 Demonstrates Rapid and Sustained Hair Regrowth in Validated Murine Model of Alopecia Areata (AA) [Yahoo! Finance]
1/27
06:55 am
acrs
Low
Aclaris Therapeutics’ Novel ITK/JAK3 Inhibitor ATI-2138 Demonstrates Rapid and Sustained Hair Regrowth in Validated Murine Model of Alopecia Areata (AA)
1/21
08:00 am
acrs
Medium
Aclaris Therapeutics (NASDAQ:ACRS) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.
11/6/2025
06:59 am
acrs
0.4%
BEAT
8/7/2025
06:59 am
acrs
1.3%
IN-LINE
5/8/2025
06:50 am
acrs
7.4%
BEAT
2/27/2025
06:59 am
acrs
-13.3%
MISS
1/30
08:14 am
Initiates
Buy
Craig Hallum
Low
-1.7%
1/30
08:14 am
Initiates
Buy
Craig Hallum
Low
-1.7%
1/30
07:07 am
Initiates
BUY
CRAIG-HALLUM
Low
-0.3%
1/30
07:07 am
Initiates
BUY
CRAIG-HALLUM
Low
-0.3%
1/28
08:41 am
Reiterates
Buy
Buy
HC Wainwright
Medium
-9.5%
1/21
12:32 pm
acrs
Medium
Form SCHEDULE 13G/A Aclaris Therapeutics, Filed by: BlackRock, Inc.
1/12
07:01 am
acrs
Low
Form 8-K Aclaris Therapeutics, For: Jan 12
1/9
09:00 am
acrs
Low
Form SCHEDULE 13G/A Aclaris Therapeutics, Filed by: Bonita Biotech (HK) Ltd
1/6
07:15 am
acrs
Low
Form 8-K Aclaris Therapeutics, For: Jan 06
1/5
04:32 pm
acrs
Low
Form 4 Aclaris Therapeutics, For: Jan 02 Filed by: Walker Neal
Show more
Top News Gainers
9/16 Aclaris Therapeutics’ A-101 45% Topical Solution Meets Primary and All Secondary Efficacy Endpoints in Pivotal Phase 3 Trial for the Treatment of Common Warts (THWART-2) 63.6%
11/7 Form 8-K Aclaris Therapeutics, For: Nov 07 39.3%
10/10 Aclaris Therapeutics Announces Divestiture of RHOFADE® 19.3%
1/9 Aclaris Therapeutics Announces Positive Results From Phase 1 Single and Multiple Ascending Dose Trial of ATI-450, an Investigational Oral MK2 Inhibitor 17.2%
10/15 Aclaris Therapeutics Inc (NASDAQ: ACRS) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 9.1%
7/9 Aclaris Therapeutics Announces Issuance of Additional Orange Book Listable Patent Covering RHOFADE® (Oxymetazoline Hydrochloride) Cream, 1% 9.1%
12/19 Form SC 13D/A Aclaris Therapeutics, Filed by: Arkin Moshe 8.8%
9/5 Aclaris Therapeutics Inc (NASDAQ: ACRS) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 8.6%
10/31 Aclaris Therapeutics to Announce Third Quarter 2019 Financial Results on November 7, 2019 8.0%
2/10 Form SC 13G/A Aclaris Therapeutics, Filed by: Man Group plc 7.9%
Top News Decliners
6/26 Aclaris Therapeutics Announces Phase 2 Clinical Trial of ATI-502 Topical in Patients with Alopecia Areata Did Not Meet Endpoints -52.1%
7/30 Glancy Prongay & Murray LLP Files Securities Class Action on Behalf of Aclaris Therapeutics, Inc. Investors (ACRS) -39.0%
2/25 Form 10-K Aclaris Therapeutics, For: Dec 31 -22.2%
8/8 Form 10-Q Aclaris Therapeutics, For: Jun 30 -13.5%
9/25 DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Aclaris Therapeutics, Inc. (NASDAQ: ACRS) and Encourages Aclaris Investors to Contact the Firm -11.7%
11/21 Form 8-K Aclaris Therapeutics, For: Nov 21 -11.2%
3/31 Form 8-K Aclaris Therapeutics, For: Mar 30 -11.1%
9/17 Aclaris Therapeutics to Hold R&D Day -10.9%
3/6 Form SC 13G Aclaris Therapeutics, Filed by: Samsara BioCapital, L.P. -10.8%
5/8 Form 10-Q Aclaris Therapeutics, For: Mar 31 -10.0%
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.
Click Here To Register For The Live Online Workshop
In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview
Earnings Week Wrap-up and Takeaways
Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix
Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More
The Smart Way to Ten Minutes Per Day

Information

Support

Contact us

20715 N Pima Rd #F108
Scottsdale, AZ 85255
Email: info@newsquantified.com
Copyright Ⓒ News Quanitifed LLC. 1.1.3